LAUSR

Background The purpose of this review is to give an update on myelin-associated glycoprotein (MAG) neuropathy. Recent Findings There are several recent developments in anti-MAG neuropathy, with the major one being the retrospective analysis of 50 clinical trials that showed that at least a 50% reduction in anti-MAG levels is associated with a therapeutic response. Other updates address antibody levels needed for a positive test, response, and exacerbations to therapy and the type of antibody more associated with malignancy. Implications for Practice Anti-MAG neuropathy is heterogeneous, and the natural history of the disease continues to be refined. Treatment options are being explored for refractory disease.